Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...

In the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market.

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...

When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

Tuesday, online health and wellness company Hims & Hers announced its intent to acquire European digital healthcare provider Zava in an all-cash deal. | The deal is expected to close in the second ...